{"entity":{"id":"nct06014658","kind":"trial","name":"Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Antibody-Drug Conjugate in advanced solid tumours, run by MBrace Therapeutics, now recruiting.","summary":"Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT06014658 by MBrace Therapeutics, with 130 participants planned, started 2023-11-07 and due to reach its primary completion in 2026-07. Interventions recorded: Antibody-Drug Conjugate.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06014658","url":"https://clinicaltrials.gov/study/NCT06014658"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["mbrace-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06014658","phase":"1/2","setting":"A Multicenter, Open-label, Phase 1/1b / Phase 2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors","sponsor":"MBrace Therapeutics","enrolled":130,"outcomes":[]},"route":"/trials/nct06014658/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"mbrace-therapeutics","kind":"company","name":"MBrace Therapeutics","route":"/companies/mbrace-therapeutics/"}]}}